483
AGC Biologics A/SAGC Biologics A/S – FDA 483, Nov 5, 2019
Record Details
An FDA inspection of AGC Biologics A/S in Soeborg, Denmark, revealed significant deficiencies across manufacturing, quality assurance, and laboratory operations. The firm failed to follow master batch records, adequately investigate recurring deviations, implement corrective actions, and maintain scientifically sound laboratory controls. These issues indicate a lack of robust quality systems and control over drug substance manufacturing processes.
View Company Profile
ID · f86fe017-848d-474e-b2f5-bf381d2e68cd
Other documents for AGC Biologics A/S
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.